The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...